The Infantile Hemangioma Referral Score: A Validated Tool for Physicians

Léauté‐Labrèze, Christine; Torres, Eulàlia Baselga; Weibel, Lisa; Boon, Laurence M.; Hachem, Maya El; Vleuten, Catharina van der; Roessler, Jochen; Rubin, Agneta Troilius

doi:10.1542/peds.2019-1628

Cited by 40 publications

(56 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, interrater reliability increased to substantial agreement at step 2 (use of IHReS) in both groups. The result correlated to the findings in the validation study of IHReS in 2020 3 and also reflected that the use of assisting instrument (IHReS) can help physicians in making their decision to refer patients with IHs for treatment. Our findings revealed that there was an increase in mutual agreement and acceptance after using IHReS not only among non-expert physicians-the IH experts also had benefited by the use of this score with an increased interrater reliability; Fleiss' Kappa in IHs experts were 0.42 at step 1 and 0.80 at step 2, respectively.…”

Section: Discussionsupporting

confidence: 75%

“…Léauté-Labrèze et al recently developed IHReS as an initial tool for primary care physicians to make their decision to refer patients to expert centres. 3 This is a two-step easy-to-use tool for non-expert physicians, provided with some drawing pictures indicating striking location and practical notice points in making decisions. This tool is free to use and is available to be downloaded from www.…”

Section: Discussionmentioning

confidence: 99%

“…Léauté-Labrèze et al recently proposed the Infantile Hemangioma Referral Score (IHReS) as an initial tool for primary care physicians to make their decisions to refer patients to expert centres. 3 This tool was developed by the experts from seven different countries across the European countries. It had a high sensitivity of 96.9% which is suited for screening purposes.…”

Section: Open Accessmentioning

confidence: 99%

See 2 more Smart Citations

Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment

Chitpiromsak

Techasatian

Jetsrisuparb

2021

bmjpo

View full text Add to dashboard Cite

BackgroundThe general paediatricians and primary care physicians sometimes face immense difficulty in referral judgements regarding which infantile hemangiomas (IHs) require referrals and when is the appropriate time to refer IHs for treatment. This resulted in the treatment being delayed beyond IHs’ critical timeframe. The Infantile Hemangioma Referral Score (IHReS) has been recently developed, with the aim to solve this problem.ObjectivesThe objective of the present study is to evaluate the reliability of IHReS and to assess the possibility of using this instrument in our country where a similar problem of delaying treatment of IHs is currently existing.MethodsThe present study was a prospective, cross-sectional study. Thirteen selected clinical cases were used to assess the reliability of IHReS among physicians who may have had the chance to deal with patients with IHs. The target physicians across the country were asked to participate in the study via an online platform (Google Forms) to decide whether to refer patients with IHs for treatment or observe. There were 3 steps of assessment: step 1, usual practice evaluation; step 2, using IHReS; step 3, retesting by using IHReS.ResultsSubstantial agreement was observed after using IHReS (step 2) for interrater reliability, with Fleiss’ Kappa values of 0.80 and 0.78 among IH experts and non-expert physicians, respectively. Regarding repeatability, in the test–retest assessments, Cohen’s Kappa coefficient values revealed almost perfect agreement in intrarater repeatability for both experts and non-expert physicians (1.00).ConclusionIHReS is a simple, easy-to-assess tool for non-expert physicians. The benefit in the increase of interrater agreement was found in both IH experts and non-expert physicians. It has had the reliability to be used in making referral decisions regarding patients with IH for treatment among Thai physicians. Using IHReS can improve clinical outcomes by identifying which patient needs early intervention to minimise the possible complications.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Section: Open Accessmentioning

confidence: 99%

See 1 more Smart Citation

Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment

Chitpiromsak

Techasatian

Jetsrisuparb

2021

bmjpo

View full text Add to dashboard Cite

show abstract

“…Methods for initiation of oral propranolol have evolved over time. [2][3][4][5][6][7][8][9] Consensus recommendations prior to the FDA/EMA approval in 2014 included the following 10 : (a) screening for contraindications to propranolol, (b) performing or obtaining documentation of, a recent normal cardiovascular and pulmonary history and examination, (c) obtaining key historical data including poor feeding, dyspnea, tachypnea, diaphoresis, wheezing, heart murmur, or family history of heart block or arrhythmia, and (d) prolonged in-office monitoring. The FDA/EMA-approved administration monitoring recommendations include in-office heart rate (HR) and blood pressure (BP) monitoring for 2 hours after the first dose of propranolol or for increasing the dose (>0.5 mg/kg/d) for infants 5 weeks of adjusted gestational age or older.…”

Section: Potential Risks Associated With Betablocker Treatmentmentioning

confidence: 99%

Management of infantile hemangiomas during the COVID pandemic

Frieden

Püttgen

Drolet

et al. 2020

Pediatric Dermatology

View full text Add to dashboard Cite

The COVID-19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas (IH) can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long-term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of IH via telemedicine. FDA/EMAapproved monitoring guidelines, clinical practice guidelines, and relevant, up-to-date Pediatric Dermatology FRIEDEN Et al.

show abstract

“…Recently, the Infantile Hemangioma Referral Score (IHReS) was developed, which is a tool for primary care providers, aiding decisions on which patients to refer 33 . It consists of 6–12 questions and can be completed online.…”

Section: Evaluation Of Infantile Haemangiomas and Patients/familiesmentioning

confidence: 99%

News on infantile haemangioma. Part 2: therapy and evaluation

2021

View full text Add to dashboard Cite

Infantile haemangioma (IH) is the most frequently occurring tumour of childhood. While benign, in more than half of the cases, less or more severe sequelae can be observed. In Part 1 of this review, we discussed the clinical course and pathomechanism of IHs. In Part 2 of this state-of-the-art review, we will discuss the current management of IH and focus on the working mechanism of b-blockers in IHs. Furthermore, we will discuss options for the evaluation of patients and their families (quality of life and family burden), as well as for the evaluation of IHs by healthcare providers, such as assessments of activity and severity. This review will update the reader on the working mechanism of propranolol in IHs and offer an oversight of tools (questionnaires and scoring systems) that can be used in clinical practice or for research.

show abstract

The Infantile Hemangioma Referral Score: A Validated Tool for Physicians

Cited by 40 publications

References 17 publications

Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment

Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment

Management of infantile hemangiomas during the COVID pandemic

News on infantile haemangioma. Part 2: therapy and evaluation

Contact Info

Product

Resources

About